Researchmoz added Most up-to-date research on "Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports.

Albany, NY -- (SBWire) -- 12/29/2015 --Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is generally considered an effective treatment for localized tumors, however the management of recurrent and later-stage disease is largely reliant on cytotoxic chemotherapy regimens.

A highly active ovarian cancer pipeline contains an array of diverse molecule types and molecular targets, in contrast to the market. With the diversity in the pipeline, there is hope that innovative products can make it to market to provide patients with greater therapeutic options, while meeting unmet needs within ovarian cancer. There are 179 ovarian cancer pipeline products associated with a first-in-class molecular target representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target. Such a diverse and innovative pipeline implies that approaches to ovarian cancer treatment are changing and first-in-class development is playing a significant role in this.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=499491

Scope

Chemotherapy based regimens continue to dominate the market, which has seen few new entrants over the past decade. Lynparza (olaparib) is a key new entrant; however it is only effective in a small patient subset.
What survival benefits do current therapies provide?
What are the current unmet needs that the pipeline needs to address?
The pipeline places increased focus on targeted therapies, including a large number of therapies targeting common oncogenic pathways and signaling intermediates such as PI3K/Akt.
What potential do mAbs have in ovarian cancer treatment?
Will pipeline diversity translate to clinically and commercially successful therapies?
How are common target families, such as intracellular signal transduction associated with pathophysiology?
52% of pipeline products act on a first-in-class target, which is higher than the oncology and industry averages.
Do first-in-class products show strong progression into the later stages?
Why is the greatest number of first-in-class products seen in signal transduction?
First-in-class products differ substantially in their clinical potential, based on their alignment to disease causing pathways
How well are first-in-class targets, such as Notch, aligned to known disease causing pathways?
Which targets are specifically found in early-stage development?
What is the industry-wide interest in these targets?
Co-development deals for first-in-class products are typically higher value than non-first-in-class counterparts.
To what extent does first-in-class status influence deal value and phase?
Can biologics command a greater deal value than other molecule types?

Reasons to buy

This report will allow you to -

Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
Visualize the composition of the ovarian cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
Analyze the ovarian cancer pipeline, and stratify by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches the treating ovarian cancer.
Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
Identify commercial opportunities in the ovarian cancer deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of ovarian cancer therapies that are not yet involved in deals and may be potential investment opportunities.

Browse Detail Report With TOC @ http://www.researchmoz.us/frontier-pharma-ovarian-cancer-identifying-and-commercializing-firstinclass-innovation-report.html

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 4
2.1 Significant Unmet Needs in the Ovarian Cancer Market 4
2.2 High Proportion of First-in-Class Innovation offers Promise in Ovarian Cancer 4
2.3 Deal Activity Varies with First-in-Class Status 4

3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Developments Remain Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8

4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Disease Symptoms 9
4.3 Epidemiology and Etiology 9
4.4 Pathophysiology 10
4.4.1 High-Grade Serous Subtype 10
4.4.2 Low-Grade Serous Subtype 11
4.4.3 Mucinous Carcinoma Subtype 11
4.4.4 Endometrioid Carcinoma Subtype 11
4.4.5 Clear Cell Carcinoma Subtype 11
4.5 Diagnosis 12
4.6 Prognosis 12
4.7 Treatment Algorithm 12
4.7.1 Surgery 12
4.7.2 First-Line Therapy 12
4.7.3 Maintenance Therapy 14
4.7.4 Recurrent Disease and Second-Line Therapy 15
4.8 Overview of Marketed Products in Ovarian Cancer 18
4.8.1 Molecule Type and Target Analysis 18
4.8.2 Innovative Products in Ovarian Cancer Market 19
4.8.3 Unmet Needs 20

5 Assessment of Pipeline Product Innovation 21
5.1 Ovarian Cancer Pipeline by Molecule Type, Phase and Therapeutic Target 21
5.2 Comparative Distribution of Programs between Ovarian Cancer Market and Pipeline by Therapeutic Target Family 25
5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 26

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=499491

About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/